March 3, 2023March 3, 2023 CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
September 14, 2022September 14, 2022 CureLab Research Results With Cats Published in Animals Journal Results published by CureLab scientists with the University of Camerino support targeting mammary gland cancers in cats via p62 plasmid
May 12, 2022May 12, 2022 CureLab Veterinary’s DNA Plasmid, Elenavet, Designated a Biologic Veterinary Product by the European Medicines Agency CureLab Veterinary plans to obtain regulatory approval in Europe, a market with significant revenue potential
May 6, 2022May 6, 2022 CureLab Veterinary Secures Patent Protection for P62 Plasmid Therapeutic in South Korea Patent registration in South Korea enables CureLab Veterinary to pursue a market with high commercial potential
